Identification of an alternatively spliced transcript of equine interleukin-1 beta.

This research identifies a variant of equine interleukin-1 beta (IL-1 beta), a protein involved in immune response, that is shorter than the normal form due to a process called alternative splicing. The shorter variant, identified in horse blood cells, lacks a section equivalent to exon 5 in the human and mouse versions of the gene, which includes a critical cleavage site for an enzyme involved in processing the protein.

Research Methodology

• Researchers used a technique called polymerase chain reaction (PCR) to make copies of the equine IL-1 beta gene from horse peripheral blood mononuclear cells (PBMC) that had been stimulated with lipopolysaccharide (LPS), a molecule that triggers immune response. They used specific primers, or starting points, for the copying process that target the IL-1 beta gene.
• An additional, smaller fragment of DNA was found when the researchers ran the PCR product through a gel and examined the patterns of DNA. This fragment also attached to a probe designed to detect the equine IL-1 beta gene, indicating that it was a derivative of that gene.

Findings and Interpretation

• The smaller DNA fragment was sequenced and found to be 162 nucleotides shorter than the standard IL-1 beta gene. This corresponds to exon 5 in the human and mouse versions of this gene. In other words, this section of the gene had been removed by a process called alternative splicing, in which different versions of a gene can be made by including or excluding certain sections.
• This deletion does not change the reading frame, or the way the sequence is translated into protein, but it does remove a critical cleavage site for the IL-1 beta converting enzyme (ICE). This enzyme processes the IL-1 beta protein into its active form, so this deletion can potentially affect the protein’s function.
• Furthermore, the researchers found that this shorter version of the gene was also produced when horse PBMCs were stimulated with other substances, showing that it wasn’t an artifact of the LPS treatment.

Conclusion

• This research represents a significant discovery – the identification of an alternatively spliced IL-1 beta transcript in equine PBMCs. This has potential implications for our understanding of equine immune response and could be relevant for studies on human and other mammalian immune systems, given the conservation of the IL-1 beta gene across species.